CARDIAC MUSCLE MODELING DURING TREATMENT WITH SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE
DOI:
https://doi.org/10.52340/jecm.2025.02.15Keywords:
Echocardiography, Heart Failure, Sacubitril/Valsartan, Valvular regurgitationsAbstract
Background and objectives. The aim of the study was to study the cardiac muscle modeling during treatment with Sacubitril/Valsartan in patients with heart failure (HF).
Methods. To assess the treatment effects of aliskiren (follow-up period – 6 months) 60 randomly were selected patients with chronic HF of different classes. They were randomly assigned to the study groups. 55 patients treated Sacubitril/Valsartan (24/26 mg), and finished the study.
Results. Significant changes have not observed for almost all echocardiographic parameters except EF. It increased significantly from 34.2% baseline to 37.4% after 6 months of the treatment initiation (p<0.001). mitral valve regurgitations (MVRs) of grade 4 was reduced, the percentage values of the MVRs of 2nd and 3rd grades were not decreased. although Tricuspid valve regurgitation (TVR) of grade 4 was reduced, the percentage values of the TVRs of 2nd and 3rd grades were not decreased significantly. The percentage value of the TVRs of 1st grade was increased.
Conclusion. Based on the evaluation of the effects of 6-months’ treatment of the HF patients with Sacubitril/Valsartan, it may be concluded that Sacubitril/Valsartan shows better results in terms of impact on the heart echocardiographic parameters, but it did not show any significant effect on the valvular regurgitations. To obtain more strong evidences, it is necessary to continue the study to provide the evidence-based results and conclusions.
Downloads
References
AHA Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2023 Update: A Report From the American Heart Association. Circulation. 2023; 147: e93–e621 (DOI Link: htpps://doi.org/10.1161/CIR.0000000000001123)
Vasan RS, Enserro DM, Beiser AS, Xanthakis V. Lifetime Risk of Heart Failure Among Participants in the Framingham Study. J Am Coll Cardiol. 2022; 79(3): 250-263 (DOI Link: htpps://doi.org/10.1016/j.jacc.2021.10.043)
Shahim B, Kapelios CJ, Savarese G, Lund LH. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023; 9: e11 (DOI Link: htpps://doi.org/10.15420/cfr.2023.05)
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020; 396: 1204–22 (DOI Link: htpps:// doi.org/10.1016/S0140-6736(20)30925-9)
van Riet EES, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016; 18: 242–52 (DOI Link: htpps:// doi.org/10.1002/ejhf.483)
Chandra A, Vaduganathan M, Lewis EF, Claggett BL, et al. PARAGON-HF Investigators Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019; 7(10): 862-874. (DOI Link: htpps:// doi.org/10.1016/j.jchf.2019.05.015)
Jia G, Aroor AR, Hill MA, Sowers JR. Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 2018; 72(3): 537-548. (DOI Link: htpps:// doi.org/10.1161/HYPERTENSIONAHA.118.11065)
Te Riet L, van Esch JH, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015; 116(6): 960-75 (DOI Link: htpps:// doi.org/10.1161/CIRCRESAHA.116.303587)
Luo Y, Chen Q. Efficacy of aliskiren supplementation for heart failure: a meta-analysis of randomized controlled trials. Herz. 2019; 44(5): 398-404 (DOI Link: htpps://doi.org/10.1007/s00059-018-4679-1)
Zhao Q, Shen J, Lu J, Jiang Q, Wang Y. Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews. BMC Cardiovasc Disord. 2020; 20(1):179 (DOI Link: htpps://doi.org/10.1186/s12872-020-01442-z)
Trivedi RK, Polhemus DJ, Li Z, Yoo D, Koiwaya H, Scarborough A, et al. Combined angiotensin receptor-neprilysin inhibitors improve cardiac and vascular function via increased NO bioavailability in heart failure. J Am Heart Assoc. 2018; 7:8268 (DOI Link: htpps://doi.org/10.1161/JAHA.117.008268)
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al.. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019; 322:1077–84 (DOI Link: htpps://doi.org/10.1001/jama.2019.12843)
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018; 36: e12435 (DOI Link: htpps://doi.org/10.1111/1755-5922.12435)
Von Elm E, Altman DG, Egger M. STROBE Initiative, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457. (DOI Link: https://doi.org/10.1016/S0140-6736(07)61602-X)
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation. 2019; 139(11): 1354-1365 (DOI Link: htpps://doi.org/doi:10.1161/CIRCULATIONAHA.118.037077)
Yenercag M, Arslan U, Dereli S, et al. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging. 2021; 37(1):165-173 (DOI Link: htpps://doi.org/10.1007/s10554-020-01973-8)
Downloads
Published
How to Cite
Issue
Section
